The majority of insulin-like growth factor (IGF)-I and IGF-II circulate in the serum as a complex with the insulin-like growth factor binding protein (IGFBP)-3 or IGFBP-5, and an acid-labile subunit (ALS). The function of ALS is to prolong the half-life of the IGF-I-IGFBP-3/IGFBP-5 binary complexes. Fourteen different mutations of the human IGFALS gene have been identified in 17 patients, suggesting that ALS deficiency may be prevalent in a subset of patients with extraordinarily low serum levels of IGF-I and IGFBP-3 that remain abnormally low upon growth hormone stimulation. Postnatal growth was clearly affected. Commonly, the height standard deviation score before puberty was between –2 and –3, and approximately 1.4 SD shorter than the midparental height SDS. Pubertal delay was found in 50% of the patients. Circulating IGF-II, IGFBP-1, -2 and -3 levels were reduced, with the greatest reduction observed for IGFBP-3. Insulin insensitivity was a common finding, and some patients presented low bone mineral density. Human ALS deficiency represents a unique condition in which the lack of ALS proteins results in the disruption of the entire IGF circulating system. Despite a profound circulating IGF-I deficiency, there is only a mild impact on postnatal growth. The preserved expression of locally produced IGF-I might be responsible for the preservation of linear growth near normal limits.

Keywords:
Acid-labile subunit, Insulin-like growth factor-I, Insulin-like growth factor binding protein, Growth hormone insensitivity, Insulin insensitivity, IGFALS gene mutations
1.
Samani AA, Yakar S, LeRoith D, Brodt P: The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev 2007;28:20–47.
2.
Liu JP, Baker J, Perkins AS, Robertson EJ, Efstratiadis A: Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igf1r). Cell 1993;75:59–72.
3.
Woods KA, Camacho-Hübner C, Savage MO, Clark AJL: Intrauterine growth retardation and postnatal growth failure associated with deletion of the insulin-like growth factor I gene. N Engl J Med 1996;335:1363–1367.
4.
Walenkamp MJ, Karperien M, Pereira AM, Hilhorst-Hofstee Y, van Doorn J, Chen JW, Mohan S, Denley A, Forbes B, van Duyvenvoorde HA, van Thiel SW, Sluimers CA, Bax JJ, de Laat JA, Breuning MB, Romijn JA, Wit JM: Homozygous and heterozygous expression of a novel insulin-like growth factor-I gene mutation. J Clin Endocrinol Metab 2005;90:2855–2864.
5.
Bennet A, Wilson DM, Liu F, Nagashima R, Rosenfeld RG, Hintz RL: Levels of insulin-like growth factors I and II in human cord blood. J Clin Endocrinol Metab 1983;57:609–612.
6.
Rosenfeld RG, Wilson DM, Lee PD, Hintz RL: Insulin-like growth factors I and II in evaluation of growth retardation. J Pediatr 1986;109:428–433.
7.
Boisclair YR, Rhoads RP, Ueki I, Wang J, Ooi GT: The acid-labile subunit (ALS) of the 150 kDa IGF-binding protein complex: an important but forgotten component of the circulating IGF system. J Endocrinol 2001;170:63–70.
8.
Rosenfeld RG, Belgorosky A, Camacho-Hübner C, Savage MO, Wit JM, Hwa V: Defects in growth hormone receptor signaling. Trends Endocrinol Metab 2007;18:134–141.
9.
Domené HM, Bengolea SV, Martínez AS, Ropelato MG, Pennisi P, Scaglia P, Heinrich JJ, Jasper HG: Deficiency of the circulating insulin-like growth factor system associated with inactivation of the acid-labile subunit gene. N Engl J Med 2004;350:570–577.
10.
Janosi JB, Ramsland PA, Mott MR, Firth SM, Baxter RC, Delhanty PJ: The acid-labile subunit of the serum insulin-like growth factor-binding protein complexes: structural determination by molecular modeling and electron microscopy. J Biol Chem 1999;274:23328–23332.
11.
Janosi JB, Firth SM, Bond JJ, Baxter RC, Delanthy PJ: N-linked glycosilations and sialylations of the acid labile subunit. J Biol Chem 1999;74:5292–5298.
12.
Arquier N, Géminard C, Bourouis M, Jarretou G, Honegger B, Paix A, Léopold P: Drosophila ALS regulates growth and metabolism through functional interaction with insulin-like peptides. Cell Metab 2008;7:333–338.
13.
Haluzik M, Yakar S, Gavrilova O, Setser J, Boisclair Y, LeRoith D: Insulin-resistance in the liver-specific IGF-I gene-deleted mouse is abrogated by deletion of the acid-labile subunit of the IGF-binding protein-3 complex. Diabetes 2003;52:2483–2488.
14.
Ueki I, Ooi GT, Tremblay ML, Hurst KR, Bach LA, Boisclair YR: Inactivation of the acid labile subunit gene in mice results in mild retardation of postnatal growth despite profound disruptions in the circulating insulin-like growth factor system. Proc Natl Acad Sci USA 2000;97:6868–6873.
15.
Yakar S, Rosen CJ, Beamer, Ackert-Bicknell CL, Wu Y, Liu JL, Ooi GT, Setser J, Frystyk J, Boisclair YR, LeRoith D: Circulating levels of IGF-I directly regulate bone growth and density. J Clin Invest 2002;110:771–781.
16.
Niklasson A, Ericson A, Fryer JG, Karlberg J, Larwence C, Karlberg P: An update of the Swedish reference standards for weight, length and head circumference at birth for given gestational age (1977–1981). Acta Paed Scand 1991;80:756–762.
17.
Sobradillo B, Aguirre A, Aresti U, Bilbao A, Fernández-Ramos C, Lizárragta A, Lorenzo H, Madariaga L, Rica I, Ruiz I, Sánchez E, Santamaría C, Serrano JM, Zabala A, Zurimendi B, Hernández M: Curvas y Tablas de Crecimiento (Estudios Longitudinal y Transversal). Bilbao, Fundación Faustino Orbegozo Eizaguirre, 2002, pp 1–36.
18.
Carrascosa Lezcano A, Ferrández Longás A, Yeste Fernández D, García-Dihinx Villanova J, Romo Montejo A, Copil Copil A, Almar Mendoza J, Salcedo Abizanda S, Gussinyé Canadell M, Baguer Mor L: Estudio transversal español de crecimiento 2008. Parte I: valores de peso y longitud en recién nacidos de 26–42 semanas de edad gestacional. An Pediatr (Barc) 2008;68:544–551.
19.
Wikland KA, Luo ZC, Niklasson A, Karlberg J: Swedish population-based longitudinal reference values from birth to 18 years of age for height, weight and head circumference. Acta Paediatr 2002;91:739–754.
20.
Domené HM, Martínez AS, Frystyk J, Bengolea SV, Ropelato MG, Scaglia PA, Chen JW, Heuck C, Wolthers OD, Heinrich JJ, Jasper HG: Normal growth spurt and final height despite low levels of all forms of circulating IGF-I in a patient with ALS deficiency. Horm Res 2007;67:243–249.
21.
Domené HM, Scaglia PA, Lteif A, Mahmud FH, Kirmani S, Frystyk J, Bedecarrás P, Gutiérrez M, Jasper HG: Phenotypic effect of null and haploinsufficiency of acid-labile subunit in a family with two novel IGFALS gene mutations. J Clin Endocrinol Metab 2007;92:4444–4450.
22.
Heath KE, Argente J, Barrios V, Pozo J, Díaz-González F, Martos-Moreno GA, Caimari M, Gracia R, Campos-Barros A: Primary acid-labile subunit deficiency due to recessive IGFALS mutations results in postnatal growth deficit associated with low circulating insulin growth factor (IGF)-I, IGF binding protein-3 levels, and hyperinsulinism. J Clin Endocrinol Metab 2008;93:1616–1624.
23.
van Duyvenvoorde HA, Kempers MJE, Twickler TB, van Doorn J, Gerver WJ, Noordam C, Losekoot M, Karperien M, Wit JM, Hermus ARMM: Homozygous and heterozygous expression of a novel mutation of the acid-labile subunit. Eur J Endocrinol 2008;159:113–120.
24.
Fofanova-Gambetti OV, Hwa V, Kirsch S, Pihoker C, Chiu HK, Derr MA, Rosenfeld RG: Three novel IGFALS gene mutations resulting in total ALS and severe circulating IGF-I/IGFBP-3 deficiency in children of different ethnic origins. Horm Res 2009;71:100–110.
25.
Suwanichkul A, Boisclair YR, Olney RC, Durham SK, Powell DR: Conservation of a growth hormone-responsive promoter element in the human and mouse acid-labile subunit genes. Endocrinology 2000;141:833–838.
26.
David A, Rose S, Miraki-Moud F, Metherell L, Clark A, Savage M, Camacho-Hübner C: Acid-labile subunit gene mutations: clinical, biochemical and molecular study in two unrelated families. 47th Annual Meeting of the European Society for Paediatric Endocrinology, Istanbul, Turkey, September 20–23, 2008. Horm Res 2008;70(suppl 1):31.
27.
Hwa V, Haeusler G, Pratt KL, Little BM, Frisch H, Koller D, Rosenfeld RG: Total absence of functional acid labile subunit, resulting in severe insulin-like growth factor deficiency and moderate growth failure. J Clin Endocrinol Metab 2006;91:1826–1831.
28.
Den Dunnen J, Antonarakis SE: Nomenclature for the description of human sequence variations. Hum Genet 2001;109:121–124.
29.
Firth SM, Yan X, Baxter RC: D413N mutation of the acid-labile subunit, a component of endocrine IGF complexes, causes defects in secretion and complex formation (abstract P2–651). Proc 90th Ann Meet Endocr Soc, San Francisco, 2008, p 562.
30.
Baxter RC, Martin JL, Beniac VA: High molecular weight insulin-like growth factor binding protein complex: purification and properties of the acid-labile subunit from human serum. J Biol Chem 1989;264:11843–11848.
31.
Baxter RC: Circulating levels and molecular distribution of the acid-labile (alfa)-subunit of the high molecular weight insulin-like growth factor-binding protein complex. J Clin Endocrinol Metab 1990;70:1347–1353.
32.
Guler HP, Zapf J, Schmid C, Froesch ER: Insulin-like growth factors I and II in healthy man: estimations of half-lives and production rates. Acta Endocrinol (Copenh) 1989;121:753–758.
33.
Zapf J, Hauri C, Futo E, Hussain M, Rutishauser J, Maack CA, Froesch ER: Intravenously injected insulin-like growth factor (IGF) I/IGF binding protein-3 complex exerts insulin-like effects in hypophysectomized, but not in normal rats. J Clin Invest 1995;95:179–186.
34.
Payet LD, Firth SM, Baxter RC: The role of the acid-labile subunit in regulating insulin-like growth factor transport across human umbilical vein endothelial cell monolayers. J Clin Endocrinol Metab 2004;89:2382–2389.
35.
Holman SR, Baxter RC: Insulin-like growth factor binding protein-3:factors affecting binary and ternary complex formation. Growth Regul 1996;6:42–47.
36.
Ning Y, Schuller AGP, Bradshaw S, Rotwein P, Ludwig T, Frystyk J, Pintar JE: Diminished growth and enhanced glucose metabolism in triple knockout mice containing mutations of insulin-like growth factor binding protein-3, -4, and -5. Mol Endocrinol 2006;20:2173–2186.
37.
Böni-Schnetzler M, Schnid C, Mary JL, Zimmerli B, Meier PJ, Zapf J, Schwander J, Froesch ER: Insulin regulates the expression of the insulin-like growth factor binding protein 2 mRNA in rat hepatocytes. Mol Endocrinol 1990;4:1320–1326.
38.
Ooi GT, Tseng LY, Rechler MM: Post-transcriptional regulation of insulin-like growth factor binding protein-2 mRNA in diabetic rat liver. Biochem Biophys Res Commun 1992;189:1031–1037.
39.
Frystyk J: Free insulin-like growth factors – measurements and relationships to growth hormone secretion and glucose homeostasis. Growth Horm IGF Res 2004;14:337–375.
40.
Smith WJ, Nam TJ, Underwood LE, Busby WH, Celnicker A, Clemmons DR: Use of insulin-like growth factor-binding protein-2 (IGFBP-2), IGFBP-3, and IGF-I for assessing growth hormone status in short children. J Clin Endocrinol Metab 1993;77:1294–1299.
41.
Clemmons DR, Snyder DK, Busby WH Jr: Variables controlling the secretion of insulin-like growth factor binding protein-2 in normal human subjects. J Clin Endocrinol Metab 1991;73:727–733.
42.
Ten S, Maclaren N: Insulin resistance syndrome in children. J Clin Endocrinol Metab 2004;89:2526–2539.
43.
Reaven GM, Chen YD, Hollenbeck CB, Sheu WH, Ostrega D, Polonsky KS: Plasma insulin, C-peptide, and proinsulin concentrations in obese and nonobese individuals with varying degrees of glucose tolerance. J Clin Endocrinol Metab 1993;76:44–48.
44.
Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412–419.
45.
Maddux BA, Chan A, De Filippis EA, Mandarino LJ, Goldfine ID: IGF-binding protein-1 levels are related to insulin-mediated glucose disposal and are a potential serum marker of insulin resistance. Diab Care 2006;29:1535–1537.
46.
Houssay BA: The hypophysis and metabolism. N Engl J Med 1936;214:961–986.
47.
Jørgensen JO, Krag M, Jessen N, Nørrelund H, Vestergaard ET, Møller N, Christiansen JS: Growth hormone and glucose homeostasis. Horm Res 2004;62(suppl 3):51–55.
48.
Randle PJ: Regulatory interactions between lipids and carbohydrates: the glucose fatty acid cycle after 35 years. Diab Metab Rev 1998;14:263–283.
49.
Segerlantz M, Bramnert M, Manhem P, Laurila E, Groop LC: Inhibition of the rise in FFA by Acipimox partially prevents GH-induced insulin resistance in GH-deficient adults. J Clin Endocrinol Metab 2001;86:5813–5818.
50.
Dominici FP, Argentino DP, Muñoz MC, Miquet JG, Sotelo AI, Turyn D: Influence of the crosstalk between growth hormone and insulin signalling on the modulation of insulin sensitivity. Growth Horm IGF Res 2005;15:324–336.
51.
Nilsson L, Binart N, Bohlooly-Y M, Bramnert M, Egecioglu E, Kindblom J, Kelly PA, Kopchick JJ, Ormandy CJ, Ling C, Billig H: Prolactin and growth hormone regulate adiponectin secretion and receptor expression in adipose tissue. Biochem Biophys Res Commun 2005;331:1120–1126.
52.
Kralisch S, Klein J, Lossner U, Bluher M, Paschke R, Stumvoll M, Fasshauer M: Hormonal regulation of the novel adipocytokine visfatin in 3T3-L1 adipocytes. J Endocrinol 2005;185:R1–R8.
53.
Venkatesan N, Davidson MB: Insulin resistance in rats harboring growth hormone-secreting tumors: decreased receptor number but increased kinase activity in liver. Metabolism 1995;44:75–84.
54.
Yuen KCJ, Dunger DB: Impact of treatment with recombinant human GH and IGF-I on visceral adipose tissue and glucose homeostasis in adults. Growth Horm IGF Res 2006;16:S55–S61.
55.
Clemmons DR: The relative roles of growth hormone and IGF-1 in controlling insulin sensitivity. J Clin Invest 2004;113:25–27.
56.
Yakar S, Liu JL, Fernandez AM, Wu Y, Schally AV, Frystyk J, Chernausek SD, Mejia W, Le Roith D: Liver-specific IGF-1 gene deletion leads to muscle insulin insensitivity. Diabetes 2001;50:1110–1118.
57.
Sjögren K, Wallenius K, Liu JL, Bohlooly-Y M, Pacini G, Svensson L, Törnell J, Isaksson OG, Ahrén B, Jansson JO, Ohlsson C: Liver-derived IGF-I is of importance for normal carbohydrate and lipid metabolism. Diabetes 2001;50:1539–1545.
58.
Clemmons DR: Role of insulin-like growth factor I in maintaining normal glucose homeostasis. Horm Res 2004;62(suppl 1):77–82.
59.
Dohm GL, Elton CW, Raju MS, Mooney ND, DiMarchi R, Pories WJ, Flickinger EG, Atkinson SM Jr, Caro JF: IGF-1-stimulated glucose transport in human skeletal muscle and IGF-1 resistance in obesity and NIDDM. Diabetes 1990;39:1028–1032.
60.
Soos MA, Whittaker J, Lammers R, Ullrich A, Siddle K: Receptors for insulin and insulin-like growth factor-I can form hybrid dimers: characterisation of hybrid receptors in transfected cells. Biochem J 1990;270:383–390.
61.
Turner HE, Wass JA: Modern approaches to treating acromegaly. QJM 2000;93:1–6.
62.
Beamer WG, Donahue LR, Rosen CJ, Baylink DJ: Genetic variability in adult bone density among inbred strains of mice. Bone 1996;18:397–403.
63.
Hildebrand T, Laib A, Muller R, Dequeker J, Ruegsegger P: Direct three-dimensional morphometric analysis of human cancellous bone: microstructural data from spine, femur, iliac crest, and calcaneus. J Bone Miner Res 1999;14:1167–1174.
64.
Domené HM, Bengolea SV, Jasper HG, Boisclair YR: Acid-labile subunit deficiency: phenotypic similarities and differences between human and mouse. J Endocrinol Invest 2005;28:43–46.
65.
Hiney JK, Ojeda SR, Dees WL: Insulin-like growth factor I: a possible metabolic signal involved in the regulation of female puberty. Neuroendocrinology 1991;54:420–423.
© 2009 S. Karger AG, Basel
2009
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.